一、中文名称：西妥昔单抗
二、产品描述：Cetuximab是一种嵌合型IgG1的EGFR单克隆抗体，可抑制EGFR与其配体相互作用。用于细胞实验时，可以使用人 IgG 抗体作为同型对照。（适用于人源及非人源化小鼠）。
三、产品详情：
种属反应性：Human
宿主：Chimeric
同种型：IgG1-kappa
克隆类型：Monoclonal
靶标：HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB
浓度：5.33 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS-PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession 号：P00533
克隆号：Cetuximab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
别名：Fab C225, IMC-225, cetuximab-IR700, CAS: 205923-56-4
四、参考文献：
1. Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial. PMID: 32687588
2. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin. PMID: 31989702
3. Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients. PMID: 31653970
4. Cost-effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer. PMID: 35543585
5. L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab. PMID: 37557179
6. Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance. PMID: 34245856
7. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. PMID: 36522816
8. Comparative Elucidation of Cetuximab Heterogeneity on the Intact Protein Level by Cation Exchange Chromatography and Capillary Electrophoresis Coupled to Mass Spectrometry. PMID: 32105056
9. RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using (47)Sc-conjugated cetuximab. PMID: 37438719
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址： https://www.biolabreagent.com/product/99/3687.html
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
